首页> 美国卫生研究院文献>Clinical and Diagnostic Laboratory Immunology >Prolonged Protection against Intranasal Challenge with Influenza Virus following Systemic Immunization or Combinations of Mucosal and Systemic Immunizations with a Heat-Labile Toxin Mutant
【2h】

Prolonged Protection against Intranasal Challenge with Influenza Virus following Systemic Immunization or Combinations of Mucosal and Systemic Immunizations with a Heat-Labile Toxin Mutant

机译:系统性免疫或粘膜和全身性免疫与不耐热毒素突变体联合使用后针对流感病毒的鼻内攻击提供了长期保护。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Seasonal influenza virus infections cause considerable morbidity and mortality in the world, and there is a serious threat of a pandemic influenza with the potential to cause millions of deaths. Therefore, practical influenza vaccines and vaccination strategies that can confer protection against intranasal infection with influenza viruses are needed. In this study, we demonstrate that using LTK63, a nontoxic mutant of the heat-labile toxin from Escherichia coli, as an adjuvant for both mucosal and systemic immunizations, systemic (intramuscular) immunization or combinations of mucosal (intranasal) and intramuscular immunizations protected mice against intranasal challenge with a lethal dose of live influenza virus at 3.5 months after the second immunization.
机译:季节性流感病毒感染在世界范围内引起相当大的发病率和死亡率,并且存在大流行性流感的严重威胁,有可能导致数百万人死亡。因此,需要实用的流感疫苗和疫苗接种策略,这些疫苗和疫苗接种策略可以保护流感病毒免于鼻内感染。在这项研究中,我们证明了使用LTK63(一种来自大肠杆菌的热不稳定毒素的无毒突变体)作为黏膜和全身免疫,全身(肌内)免疫或黏膜(鼻内)和肌肉内免疫组合的佐剂可保护小鼠在第二次免疫后3.5个月,用致死剂量的活流感病毒对鼻内攻击。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号